A

AlloVir

123 employees

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Infectious disease
Pharmaceutical
Cell Therapy
Clinical Trials
Therapeutic developer

Date founded

2013

Funding rounds raised

Total raised

$127M

from 11 investors over 11 rounds

A

AlloVir raised $127M on July 27, 2022

Investors: -, GMT Capital, The Invus Group, Redmile Group and Gilead Sciences

A

AlloVir raised $120M on May 23, 2019

Investors: Gilead Sciences, Redmile Group, Leerink Partners LLC, Research Division, Samsara BioCapital and The Invus Group

A

AlloVir raised $9M on August 18, 2017

Investors: Cancer Prevention and Research Institute of Texas

FAQ